Yue Zhang

Dr. Yue Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZCZhan Chen
Zhan Chen
RLRui-Min Lin
Rui-Min Lin
YBYue-Kui Bai
Yue-Kui Bai
YZYue Zhang
Yue Zhang
With gastrointestinal tract as the origin, gastrointestinal stromal tumor (GIST) is recognized as the very widespread mesenchymal tumor. A precise prognostic model of survival is required to guide the treatment options of patients with GIST. This study was designed to map the overall survival (OS) and cancer-specific survival (CSS) of GIST patients. According to the Surveillance, Epidemiology, and End Results (SEER) program database, we acquired the data of 6,713 patients with GIST who were diagnosed between 2004 and 2014. We randomly separated the patients into training (n = 4,699) and validation (n = 2,014) groups. To assess the prognostic impact of multiple clinical parameters, the Kaplan-Meier approach and the Cox proportional hazards regression model were adopted, where essential prognostic variables were combined to create nomograms. The consistency index and curve of calibration had been adopted to assess nomogram discrimination ability and prediction accuracy. A multifactor analysis of the training cohort showed that age, gender, size of tumor, location, and primary surgery were remarkably related to survival, and these variables were applied to create nomograms. The nomogram demonstrated excellent accuracy in estimating 2-, 3-, and 5-year OS and CSS, with a C-index of 0.740 (95% confidence interval [CI], 0.723-0.757) for OS and 0.743 (95% CI, 0.718-0.768) for CSS. In the validation cohort, the nomogram-predicted C-index was 0.741 for OS (95%CI, 0.717-0.765) and 0.746 (95%CI, 0.713-0.779) for CSS. All calibration curves showed good consistency between predicted and actual survival. A new nomogram was created and verified to predict the OS and CSS of patients with GIST. These new prognostic models can help enhance the accuracy of survival outcome predictions, thus facilitating to provide constructive therapeutic suggestions.

8 April 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YZYue Zhang
Yue Zhang
XCXiao-Lei Chen
Xiao-Lei Chen
Wenming ChenWenming Chen
Wenming Chen
HZHebing Zhou
Hebing Zhou
To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram. The discriminative ability and predictive accuracy of the nomogram were evaluated using the index of concordance (C-index) and calibration curves and compared with the five staging systems currently used for MM. Multivariate analysis of the training cohort revealed that the age at diagnosis, clonal bone marrow plasma cells, serum lactate dehydrogenase, serumβ2-microglobulin, and del (17p) were independent risk factors for OS and were used to establish the nomogram. The C-index value of the nomogram for predicting OS was 0.749, which was significantly higher than the C-indices of the five most common staging systems currently used for MM. In the validation cohort, the C-index for nomogram-based predictions was 0.711 for OS, and the nomogram discrimination was better than the above mentioned five staging systems (P<0.001). All calibration curves revealed good consistency between predicted and actual survivals. The proposed nomogram is more accurate in predicting the prognoses of patients with newly diagnosed MM.

26 November 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YTYing Tian
Ying Tian
YZYue Zhang
Yue Zhang
WZWan-Qiu Zhu
Wan-Qiu Zhu
XCXiao-Lei Chen
Xiao-Lei Chen
HZHebing Zhou
Hebing Zhou
Wenming ChenWenming Chen
Wenming Chen
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.

20 July 2024 in Cytokine
Verified
Journal Article
Open access
ZCZhan Chen
Zhan Chen
TCTingting Chen
Tingting Chen
RLRuimin Lin
Ruimin Lin
YZYue Zhang
Yue Zhang
Inflammatory proteins are implicated in the progression of abdominal aortic aneurysms (AAA); however, it remains debated whether they are causal or consequential. This study aimed to assess the influence of circulating inflammatory proteins on AAA via two-sample Mendelian randomization (MR) and colocalization analysis. Summary data on 91 circulating inflammatory protein levels were extracted from a comprehensive protein quantitative trait loci (pQTL) study involving 14,824 individuals. Genetic associations with AAA were derived from the FinnGen study (3,869 cases and 381,977 controls). MR analysis was conducted to assess the relationships between proteins and AAA risk. Colocalization analysis was employed to explore potential shared causal variants between identified proteins and AAA. Using a two-sample bidirectional MR study, our findings suggested that genetically predicted elevated levels of TGFB1 (OR = 1.21, P = 0.003), SIRT2 (OR = 1.196, P = 0.031) and TNFSF14 (OR = 1.129, P = 0.034) were linked to an increased risk of AAA. Conversely, genetically predicted higher levels of CD40 (OR = 0.912, P = 0.049), IL2RB (OR = 0.839, P = 0.028) and KITLG (OR = 0.827, P = 0.008) were associated with a decreased risk of AAA. Colocalization analyses supported the association of TGFB1 and SIRT2 levels with AAA risk. The proteome-wide MR and colocalization study identified TGFB1 and SIRT2 as being associated with the risk of AAA, warranting further investigation as potential therapeutic targets.

5 December 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
YTYing Tian
Ying Tian
XGXiaobin Guo
Xiaobin Guo
YZYue Zhang
Yue Zhang
Novel therapeutic agents have substantially improved multiple myeloma (MM) survival, making cardiovascular disease (CVD) a predominant cause of non-cancer

5 September 2025 in Medicine
Verified
Journal Article
Open access
YTYing Tian
Ying Tian
Wenming ChenWenming Chen
Wenming Chen
YZYue Zhang
Yue Zhang
The causal relationship between immune cell signatures and multiple myeloma (MM) pathobiology remains incompletely understood. This study aimed to explore the bidirectional causal associations between 731 circulating immune cell traits and MM risk using a two-sample, bidirectional Mendelian randomization (MR) approach. Two-sample MR analyses were conducted utilizing genome-wide association study (GWAS) summary statistics for 731 immune cell phenotypes and MM GWAS datasets. Sensitivity analyses were performed to assess the robustness and reliability of the findings. Furthermore, meta-analyses were conducted on specific immune cell traits identified through the primary MR analyses to reinforce causal inferences. We identified 11 immune cell traits across 3 immune profiles – absolute cell count (AC), relative cell (RC) frequency, and median fluorescence intensity (MFI) – that exhibited significant causal associations with MM. Three immune traits were associated with an increased risk of MM: CD39 + CD8br %CD8br ( P  < .001), CD20 on CD20 − CD38 − cells ( P = .002), and CD38 on transitional cells ( P  < .001). Conversely, 8 immune traits were found to confer a protective effect against MM, including CD11c + monocyte AC ( P = .002), Im myeloid-derived suppressor cell (MDSC) %CD33 dim HLA-DR − CD66b − ( P = .002), CD8 dim %T cell ( P  < .001), CD8 dim %leukocyte ( P  < .001), CD24 on CD24 + CD27 + cells ( P = .003), CD4 on naive CD4 + cells ( P  < .001), CD11b on Mo MDSCs ( P = .002), and HLA-DR on CD33 dim HLA-DR + CD11b − cells ( P  < .001). The reverse MR analysis demonstrated a significant causal association between the expression of CD19 on CD24 + CD27 + B cells and CD16 on CD14 + CD16 + monocytes in MM. These findings were validated through sensitivity tests and meta-analyses, which confirmed the robustness of the results and the absence of significant heterogeneity. Our bidirectional MR analyses provide compelling evidence for causal relationships between specific immune cell phenotypes and MM risk. These insights deepen the understanding of immune system dysregulation in MM pathogenesis and highlight potential immune-related targets for future therapeutic interventions.